NeuroSigma, Inc.

NeuroSigma, Inc. is a US-based medical technology company specializing in non-invasive neuromodulation solutions for neuropsychiatric disorders such as ADHD, utilizing innovative devices to improve patient outcomes. Founded in 2022 and headquartered in Los Angeles, US, NeuroSigma, Inc. focuses on developing neuromodulation devices.

The company has closed one deal to date. In January 2026, NeuroSigma, Inc. raised USD 1 million in venture funding from Checkmate Capital. NeuroSigma primarily focuses on its flagship product, the Monarch eTNS® System, which is the first FDA-cleared device specifically designed to treat pediatric attention deficit hyperactivity disorder (ADHD) in children aged 7 to 12 years who are not currently on prescription medications.

This non-invasive device utilizes trigeminal nerve stimulation to deliver gentle electrical pulses, effectively modulating neurological functions associated with attention and mood. The device is intended for use at home, under the supervision of a caregiver, during sleep. NeuroSigma's technology addresses significant unmet clinical needs within the multi-billion-dollar neurological and neuropsychiatric markets, targeting conditions such as autism spectrum disorder (ASD), epilepsy, and depression. The company primarily serves healthcare providers and patients in the United States and certain international markets where the device has been cleared for use.

NeuroSigma’s revenue generation is structured around the sale of its Monarch eTNS® System, which is available exclusively by prescription. The company engages in direct-to-consumer transactions facilitated through healthcare providers, who prescribe the device to eligible patients. Revenue is derived from the sale of each device, along with potential recurring revenue from follow-up services and patient management systems. The company may also establish partnerships with medical institutions for clinical trials and research, expanding its market presence.

The pricing structure for the Monarch eTNS® System is based on individual sales through healthcare channels, aligning with the company’s commitment to providing accessible and effective neuromodulation solutions for patients. The company plans to use the December 2025 funding to support the further development of its eTNS device.